Detecting and tracking circulating tumour DNA copy number profiles during first line chemotherapy in oesophagogastric adenocarcinoma

Study ID Alternative Stable ID Type
EGAS00001003695 Other

Study Description

DNA somatic copy number aberrations (SCNAs) are key drivers in oesophago-gastric adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating tumour (ct)DNA can predict treatment outcomes and reveal how SCNAs evolve during chemotherapy is unknown. We investigated this by low-coverage whole genome sequencing (lcWGS) of ctDNA from 30 patients with advanced OGA prior to first-line chemotherapy and on progression.

Study Datasets 1 dataset.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
Non-deduplicated bam files comprising Illumina HiSeq2500 SE100 low coverage whole genome data for 30 pre-treatment (BL) cfDNA samples and 20 matched post-treatment (PD) cfDNA samples.
Illumina HiSeq 2500 50

Who archives the data?

There are no publications available